Stadler WM - Search Results

1

A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.

Lara PN Jr, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. Lara PN Jr, et al. Among authors: stadler wm. Clin Cancer Res. 2006 Mar 1;12(5):1556-63. doi: 10.1158/1078-0432.CCR-05-2074. Clin Cancer Res. 2006. PMID: 16533781 Clinical Trial.

2

Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator.

Stadler WM, Richards JM, Vogelzang NJ. Stadler WM, et al. J Natl Cancer Inst. 1992 Dec 2;84(23):1835-6. doi: 10.1093/jnci/84.23.1835. J Natl Cancer Inst. 1992. PMID: 1433373 No abstract available.

3

Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer.

Stadler WM, Vogelzang NJ, Vokes EE, Charette J, Whitman G. Stadler WM, et al. Cancer Chemother Pharmacol. 1992;31(3):213-6. doi: 10.1007/BF00685550. Cancer Chemother Pharmacol. 1992. PMID: 1464158 Clinical Trial.

4

Low-dose interleukin-2 in the treatment of metastatic renal-cell carcinoma.

Stadler WM, Vogelzang NJ. Stadler WM, et al. Semin Oncol. 1995 Feb;22(1):67-73. Semin Oncol. 1995. PMID: 7855621 Review. No abstract available.

5

The cure of bladder cancer: the need for multidisciplinary efforts.

Vogelzang NJ, Stadler W, Rukstalis D. Vogelzang NJ, et al. J Urol. 1994 Mar;151(3):605-6. doi: 10.1016/s0022-5347(17)35028-0. J Urol. 1994. PMID: 8308968 No abstract available.

6

Human renal cancer carcinogenesis: a review of recent advances.

Stadler W, Vogelzang NJ. Stadler W, et al. Ann Oncol. 1993 Jun;4(6):451-62. doi: 10.1093/oxfordjournals.annonc.a058550. Ann Oncol. 1993. PMID: 8394735 Free article. Review. No abstract available.

7

High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.

Shulman KL, Stadler WM, Vogelzang NJ. Shulman KL, et al. Among authors: stadler wm. Urology. 1996 Feb;47(2):194-7. doi: 10.1016/S0090-4295(99)80414-2. Urology. 1996. PMID: 8607232

8

A phase II study of subcutaneous recombinant human interleukin-4 in metastatic renal cell carcinoma.

Stadler WM, Rybak ME, Vogelzang NJ. Stadler WM, et al. Cancer. 1995 Nov 1;76(9):1629-33. doi: 10.1002/1097-0142(19951101)76:9<1629::aid-cncr2820760920>3.0.co;2-q. Cancer. 1995. PMID: 8635068 Clinical Trial.

9

Metastatic bladder cancer: advances in treatment.

Stadler WM, Kuzel TM, Raghavan D, Levine E, Vogelzang NJ, Roth B, Dorr FA. Stadler WM, et al. Eur J Cancer. 1997 Jan;33 Suppl 1:S23-6. doi: 10.1016/s0959-8049(96)00337-1. Eur J Cancer. 1997. PMID: 9166096 Review.

10

Granulocyte-macrophage--colony stimulating factor in metastatic renal cell carcinoma: a phase II trial.

Rini BI, Stadler WM, Spielberger RT, Ratain MJ, Vogelzang NJ. Rini BI, et al. Among authors: stadler wm. Cancer. 1998 Apr 1;82(7):1352-8. doi: 10.1002/(sici)1097-0142(19980401)82:7<1352::aid-cncr19>3.0.co;2-5. Cancer. 1998. PMID: 9529028 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

339 results

Search Page